Latest Posts

11 Apr 2018

ANGIODYNAMICS TO PRESENT AT TWO INVESTOR CONFERENCES IN MAY

Michael Greiner   AngioDynamics Inc., a provider of minimally invasive medical devices for vascular access, peripheral vascular disease, surgery and oncology, will present at the following two investor conferences in May: Deutsche Bank 43rd Annual Healthcare Conference, 3:30 p.m. May 8 in Boston. President and CEO Jim Clemmer and Executive Vice

0
10 Apr 2018

VARITHENA IS AN ELEGANT SOLUTION FOR C6 ULCER

At 4 months post-treatment, Tom’s wound remained closed and he stated that he was very satisfied with the treatment.     By Kenneth Otah, MD, MSc, FACC Patients with venous ulcers make up over up more than 70 percent of nonhealing ulcers. By the time these patients are referred to

0
03 Apr 2018

AMERICAN VEIN OWNERS TEACH CUTTING EDGE VEIN PROCEDURES IN CHINA

American Vein & Vascular Institute owners Gordon F. Gibbs, MD, and Erin Gibbs have returned from 10 days in China teaching Chinese doctors contemporary vascular healthcare practices. In partnership with Medtronic, Dr. and Mrs. Gibbs recently traveled to Beijing and Shanghai, teaching 50 Chinese doctors through presentations, training sessions and

0
03 Apr 2018

BUREAUCRAT MYSTERY: CMS CANCELS EXCITE RULE TO SPEED MEDICAL DEVICE MANUFACTURING

Just when you thought the government was going to cut through its own red tape to help get medical devices to the market quicker, the U.S. Centers for Medicare & Medicaid Services (CMS) decided that it must have lost its mind. The CMS has withdrawn a proposed rule intended to

0
03 Apr 2018

BTG OPTALYSE PE TRIAL RESULTS REINFORCE SAFETY AND EFFICACY OF SHORTER, LOWER DOSE EKOS THERAPY FOR PE

BTG plc highlighted OPTALYSE PE one-year trial results, presented at the International Society on Endovascular Therapy in Florida in February. The findings confirm that bilateral pulmonary embolism (PE) patients treated in as little as two hours with a total tissue plasminogen activator (tPA) dose as low as 8mg continue to

0
SHARE

Home